Comparative Pharmacology
Head-to-head clinical analysis: METHYLPHENIDATE versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLPHENIDATE versus QUILLIVANT XR.
METHYLPHENIDATE vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
Clinical Note
moderateDexmethylphenidate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexmethylphenidate."
Clinical Note
moderateBretylium + Methylphenidate
"Bretylium may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateCyamemazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate."
Clinical Note
moderateSulpiride + Methylphenidate
Immediate-release: 2–3 hours; Extended-release: 3–4 hours (drug), 6–8 hours (beaded forms). Context: Short half-life necessitates multiple daily dosing; sustained-release formulations prolong duration.
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Renal: 90% (mostly as metabolites, primarily ritalinic acid), Fecal: <2%, Unchanged drug in urine: ~1%
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category A/B
Category C
CNS Stimulant
CNS Stimulant
"The risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate."